Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen will present at two upcoming virtual investor conferences. The 2020 RBC Capital Markets Global Healthcare Conference is scheduled for May 19, 2020, at 10:55 AM EST, and the Jefferies Virtual Global Healthcare Conference will take place on June 4, 2020, at 11:00 AM EST. Both presentations will include a fireside chat discussion and Q&A. Audio webcasts will be available on the Corbus website, with replays archived for 90 days. Corbus focuses on developing therapies targeting the endocannabinoid system for various diseases.
- None.
- None.
Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at two upcoming virtual investor conferences.
The following are the details for the conferences:
2020 RBC Capital Markets Global Healthcare Conference
- Event: Fireside Chat Discussion and Q&A
- Date and Time: Tuesday, May 19, 2020 at 10:55am EST
Jefferies Virtual Global Healthcare Conference
- Event: Fireside Chat Discussion and Q&A
- Date and Time: Thursday, June 4, 2020 at 11:00am EST
An audio webcast of the presentations will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com and replay will be available approximately one hour after each event and will be archived for 90 days following the event.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.
Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus’ clinical programs, please visit here.
Please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic, including sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com
Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com
Christina Tartaglia Stern IR, Inc.
Phone: +1 (212) 362-1200
Email: christina.targaglia@sternir.com
FAQ
What conferences will Corbus Pharmaceuticals be presenting at?
Who is presenting for Corbus Pharmaceuticals at the investor conferences?
What is the focus of Corbus Pharmaceuticals’ drug development?
What is lenabasum, and what diseases is it being evaluated for?
Are lenabasum and CRB-4001 approved for any treatments?
